Guardant Health
About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Employees: 2,021
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
106% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 31
50% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]
29% more capital invested
Capital invested by funds: $2.83B [Q3] → $3.65B (+$819M) [Q4]
10% more funds holding
Funds holding: 267 [Q3] → 295 (+28) [Q4]
7% more repeat investments, than reductions
Existing positions increased: 94 | Existing positions reduced: 88
5.85% less ownership
Funds ownership: 102.56% [Q3] → 96.71% (-5.85%) [Q4]
48% less call options, than puts
Call options by funds: $29.5M | Put options by funds: $56.8M
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$50
18%
upside
Avg. target
$55
29%
upside
High target
$60
41%
upside
12 analyst ratings
12 positive
100%
0 neutral
0%
0 negative
0%
Barclays Luke Sergott 28% 1-year accuracy 16 / 57 met price target | 30%upside $55 | Overweight Maintained | 10 Apr 2025 |
Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target | 30%upside $55 | Outperform Initiated | 10 Apr 2025 |
Stephens & Co. Mason Carrico 12% 1-year accuracy 3 / 26 met price target | 30%upside $55 | Overweight Reiterated | 26 Mar 2025 |
Morgan Stanley Shannon O'Callaghan 100% 1-year accuracy 1 / 1 met price target | 23%upside $52 | Overweight Maintained | 6 Mar 2025 |
Piper Sandler David Westenberg 43% 1-year accuracy 18 / 42 met price target | 18%upside $50 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 5 articles about GH published over the past 30 days
Positive
Investors Business Daily
4 days ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Neutral
Business Wire
1 week ago
Guardant Health to Report First Quarter 2025 Financial Results on April 30, 2025
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will.
Neutral
Business Wire
2 weeks ago
Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it has entered into an agreement with Bayshore HealthCare, a leading home and community healthcare service provider in Canada, to offer Guardant's portfolio of precision oncology tests across the continuum of cancer care through the Bayshore network of clinics in Canada. Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding Quebec), and the agre.
Neutral
MarketBeat
3 weeks ago
4 Healthcare Stocks With Massive Gains—and More to Come
The American stock markets have had a rough month as investors remain jittery over international tariff fears. While this market downturn has affected most sectors of the economy, healthcare stocks are doing exceptionally well, outperforming the general market as the most successful sector of 2025 so far.
Neutral
Business Wire
3 weeks ago
Guardant Health's Shield Blood Test Now Covered for VA Community Care Beneficiaries
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered by a key healthcare insurance program for U.S. veterans. The screening test is covered for patients receiving community care authorized by the U.S. Department of Veterans Affairs (VA) as an in-network benefit, with no copay for average-risk individuals who are age 45 or older. Following Medicare.
Positive
Seeking Alpha
1 month ago
Guardant Health: Great Buy On Dips For Strong Diagnostics Verticals Despite Premium Valuation
Guardant Health basically leads in liquid biopsy oncology diagnostics using genomic and digital technologies for early cancer detection. One of its main offerings is Guardant360, which is currently generating record revenues and growth for GH. Similarly, GH has an expanding pipeline, which includes its Reveal and Shield tests, that could significantly boost its future market potential.
Positive
Benzinga
1 month ago
Medicare To Reimburse Guardant Health's Shield Colorectal Cancer Test, Analyst Expects $10M In Revenue
On Tuesday, the Centers for Medicare & Medicaid Services (CMS) approved the Advanced Diagnostic Laboratory Test (ADLT) status for Guardant Health, Inc.'s GH Shield blood test for colorectal cancer (CRC) screening.
Neutral
Business Wire
1 month ago
Guardant Health Receives ADLT Status From CMS for Shield Blood Test
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Centers for Medicare & Medicaid Services (CMS) has approved Advanced Diagnostic Laboratory Test (ADLT) status for the Shield™ blood test for colorectal cancer (CRC) screening. The U.S. Food and Drug Administration (FDA) approved Shield in July 2024 as the first blood test for primary CRC screening. Medicare already covers the test. The CMS determination confirms.
Neutral
Business Wire
1 month ago
Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant's Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr.
Neutral
Business Wire
1 month ago
New Guardant Health/Harris Poll Survey Highlights Patient Fear and Anxiety as Major Barriers to Colorectal Cancer Screening, but Blood Test Option Offers Hope for Change
PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the results of the second annual “Closing the Gap: CRC Screening Insights” survey, which showed that nine out of ten physicians surveyed are concerned about the percentage of their patients who do not complete colorectal cancer (CRC) screening. In many cases, this is due to patient fear and anxiety, but a blood test option offers hope to increase screening rates. Conduct.
Charts implemented using Lightweight Charts™